The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21.20 - Manufacture Of Pharmaceutical Preparations
125 - 148 jobs Number of planned job losses
Announcement Date
27 September 2024
Employment effect (start)
1 October 2024
Foreseen end date
Description
Janssen Pharmaceutica, part of the Johnson & Johnson group has announced it will cut up from 125 to 148 jobs from its 5,309 employees. The restructuring, driven by the upcoming 2025 expiration of the Stelara patent (an anti-inflammatory) as well as rising costs in the pharmaceutical sector, aims to secure future profits for the facility. While no job losses are expected in the logistics department, other divisions may be affected. This concerns support services such as finance, marketing, administration, HR, research and development.
Unions have expressed their concern, noting the company’s profitability, but acknowledging the global nature of the restructuring efforts. Johnson & Johnson promises to support all employees such as providing retraining, so that they are also eligible for other jobs.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
